Axsome Therapeutics, Inc 10-Q for FY2026 Q3
Axsome Therapeutics, Inc. (AXSM)
10-Q
2026-11-02
For: 2026-09-30
View Original
Added on
November 02, 2026
About this 10-Q
Axsome Therapeutics, Inc filed this 10-Q on November 2, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Axsome Therapeutics reported $259.7 million of revenue and a $12.9 million net loss for the three months ended September 30, 2026. AUVELITY received FDA approval for agitation associated with Alzheimer’s disease in April 2026 and launched in June 2026. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $259.69M
- up 51.9% from $170.99M a year earlier
- Net loss
- $12.88M
- compared with a net loss of $47.23M a year earlier
- Diluted EPS
- -$0.25
- compared with -$0.94 a year earlier